Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.

Biotechnology

Immunovant

Immunovant's headquarters in New York, NY, United States

The Durham office is likely focused on clinical operations and program management within the biotech or pharmaceutical sectors.

People (9)

Jobs (0)

Other offices